91
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Incretin-based therapies for type 2 diabetes mellitus.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Incretin-based drugs, such as glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase 4 inhibitors, are now routinely used to treat type 2 diabetes mellitus. These agents regulate glucose metabolism through multiple mechanisms, their use is associated with low rates of hypoglycemia, and they either do not affect body weight (dipeptidyl peptidase 4 inhibitors), or promote weight loss (glucagon-like peptide-1 receptor agonists). The success of exenatide and sitagliptin, the first therapies in their respective drug classes to be based on incretins, has fostered the development of multiple new agents that are currently in late stages of clinical development or awaiting approval. This Review highlights our current understanding of the mechanisms of action of incretin-based drugs, with an emphasis on the emerging clinical profile of new agents.

          Related collections

          Author and article information

          Journal
          Nat Rev Endocrinol
          Nature reviews. Endocrinology
          Springer Science and Business Media LLC
          1759-5037
          1759-5029
          May 2009
          : 5
          : 5
          Affiliations
          [1 ] Department of Medicine, Samuel Lunenfeld Research Institute, Mt Sinai Hospital, University of Toronto, Toronto M5T 3L9, Canada.
          Article
          nrendo.2009.48
          10.1038/nrendo.2009.48
          19444259
          74d81d99-3ce8-4d5c-b10d-640e18af11c0
          History

          Comments

          Comment on this article